Eli Lilly, J&J Rise on New Data While Software Stocks Slide
Pharma giants Eli Lilly and J&J gained on fresh data releases, while software stocks reversed last week's rally heading into the final trading hour.
Eli Lilly and Johnson & Johnson shares moved higher Tuesday after both drugmakers released new clinical or market data that buoyed investor confidence, even as the broader technology sector gave back ground it had gained during the previous week's rally. The diverging moves underscored a rotation dynamic that has repeatedly emerged in 2024, with health-care names finding buyers when risk appetite in growth sectors cools.
Software stocks, which had logged meaningful advances just days earlier, came under selling pressure as traders appeared to reassess valuations heading into the final hour of the session. The retreat suggested that last week's enthusiasm may have outpaced near-term fundamentals, prompting some profit-taking before the close.
Read more Crypto Investors Shift Focus From Market Cap Back to Fundamentals →
The afternoon market snapshot was flagged in CNBC's Investing Club "Homestretch" bulletin, a daily actionable update published each weekday designed to help members navigate the last hour of trading — historically one of the most volatile and consequential windows of the session. The Club uses the note to highlight key movers and position-relevant developments.
The day's action illustrated how quickly sentiment can shift between sectors, with defensive and data-driven health-care plays absorbing flows that rotated out of momentum-driven software names. Investors tracking both spaces will likely watch for follow-through in Wednesday's session to determine whether the moves represent a durable shift or a single-day rebalancing.
Continue reading at US Top News and Analysis.
